Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.

Humans Female Breast Neoplasms / drug therapy Sentinel Lymph Node Biopsy / methods Neoadjuvant Therapy / methods Axilla / pathology Prospective Studies Lymphatic Metastasis / pathology Sentinel Lymph Node / surgery Lymph Node Excision

Axillary dissection Neoadjuvant chemotherapy Sentinel lymph node surgery

Journal

Annals of surgical oncology

ISSN: 1534-4681

Titre abrégé: Ann Surg Oncol

Pays: United States

ID NLM: 9420840

Informations de publication

Date de publication:
Oct 2023

Historique:

received: 22 03 2023

accepted: 01 06 2023

medline: 20 9 2023

pubmed: 29 6 2023

entrez: 28 6 2023

Statut: ppublish

Résumé

Axillary surgery after neoadjuvant chemotherapy (NAC) is becoming less extensive. We evaluated the evolution of axillary surgery after NAC on the multi-institutional I-SPY2 prospective trial. We examined annual rates of sentinel lymph node (SLN) surgery with resection of clipped node, if present), axillary lymph node dissection (ALND), and SLN and ALND in patients enrolled in I-SPY2 from January 1, 2011 to December 31, 2021 by clinical N status at diagnosis and pathologic N status at surgery. Cochran-Armitage trend tests were calculated to evaluate patterns over time. Of 1578 patients, 973 patients (61.7%) had SLN-only, 136 (8.6%) had SLN and ALND, and 469 (29.7%) had ALND-only. In the cN0 group, ALND-only decreased from 20% in 2011 to 6.25% in 2021 (p = 0.0078) and SLN-only increased from 70.0% to 87.5% (p = 0.0020). This was even more striking in patients with clinically node-positive (cN+) disease at diagnosis, where ALND-only decreased from 70.7% to 29.4% (p < 0.0001) and SLN-only significantly increased from 14.6% to 56.5% (p < 0.0001). This change was significant across subtypes (HR-/HER2-, HR+/HER2-, and HER2+). Among pathologically node-positive (pN+) patients after NAC (n = 525) ALND-only decreased from 69.0% to 39.2% (p < 0.0001) and SLN-only increased from 6.9% to 39.2% (p < 0.0001). Use of ALND after NAC has significantly decreased over the past decade. This is most pronounced in cN+ disease at diagnosis with an increase in the use of SLN surgery after NAC. Additionally, in pN+ disease after NAC, there has been a decrease in use of completion ALND, a practice pattern change that precedes results from clinical trials.

Sections du résumé

BACKGROUND BACKGROUND

Axillary surgery after neoadjuvant chemotherapy (NAC) is becoming less extensive. We evaluated the evolution of axillary surgery after NAC on the multi-institutional I-SPY2 prospective trial.

METHODS METHODS

We examined annual rates of sentinel lymph node (SLN) surgery with resection of clipped node, if present), axillary lymph node dissection (ALND), and SLN and ALND in patients enrolled in I-SPY2 from January 1, 2011 to December 31, 2021 by clinical N status at diagnosis and pathologic N status at surgery. Cochran-Armitage trend tests were calculated to evaluate patterns over time.

RESULTS RESULTS

Of 1578 patients, 973 patients (61.7%) had SLN-only, 136 (8.6%) had SLN and ALND, and 469 (29.7%) had ALND-only. In the cN0 group, ALND-only decreased from 20% in 2011 to 6.25% in 2021 (p = 0.0078) and SLN-only increased from 70.0% to 87.5% (p = 0.0020). This was even more striking in patients with clinically node-positive (cN+) disease at diagnosis, where ALND-only decreased from 70.7% to 29.4% (p < 0.0001) and SLN-only significantly increased from 14.6% to 56.5% (p < 0.0001). This change was significant across subtypes (HR-/HER2-, HR+/HER2-, and HER2+). Among pathologically node-positive (pN+) patients after NAC (n = 525) ALND-only decreased from 69.0% to 39.2% (p < 0.0001) and SLN-only increased from 6.9% to 39.2% (p < 0.0001).

CONCLUSIONS CONCLUSIONS

Use of ALND after NAC has significantly decreased over the past decade. This is most pronounced in cN+ disease at diagnosis with an increase in the use of SLN surgery after NAC. Additionally, in pN+ disease after NAC, there has been a decrease in use of completion ALND, a practice pattern change that precedes results from clinical trials.

Identifiants

DOI: 10.1245/s10434-023-13759-y PMID: 37380911

pubmed: 37380911

doi: 10.1245/s10434-023-13759-y

pii: 10.1245/s10434-023-13759-y

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

6401-6410

Subventions

Organisme : NCI NIH HHS

ID : P01 CA210961

Pays : United States

Organisme : NCI NIH HHS

ID : P01 CA210961

Pays : United States

Informations de copyright

Références

Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394–9.

doi: 10.1097/00000658-199509000-00016 pubmed: 7677468 pmcid: 1234825

Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997;15:2345–50.

doi: 10.1200/JCO.1997.15.6.2345 pubmed: 9196149

Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–8.

doi: 10.1097/00000658-199409000-00015 pubmed: 8092905 pmcid: 1234400

Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer–a multicenter validation study. N Engl J Med. 1998;339:941–6.

doi: 10.1056/NEJM199810013391401 pubmed: 9753708

Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33.

doi: 10.1016/S1470-2045(10)70207-2 pubmed: 20863759 pmcid: 3041644

Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250:558–66.

doi: 10.1097/SLA.0b013e3181b8fd5e pubmed: 19730235

Gimbergues P, Abrial C, Durando X, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann Surg Oncol. 2008;15:1316–21.

doi: 10.1245/s10434-007-9759-z pubmed: 18311507

Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2005;23:2694–702.

doi: 10.1200/JCO.2005.05.188 pubmed: 15837984

Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93:539–46.

doi: 10.1002/bjs.5209 pubmed: 16329089

Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol. 2009;16:551–63.

doi: 10.1016/j.acra.2009.01.026 pubmed: 19345896

Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61.

doi: 10.1001/jama.2013.278932 pubmed: 24101169 pmcid: 4075763

Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609–18.

doi: 10.1016/S1470-2045(13)70166-9 pubmed: 23683750

Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy following neoadjuvant chemotherapy in biopsy proven node positive breast cancer: the SN FNAC study. J Clin Oncol. 2013;31:1018.

doi: 10.1200/jco.2013.31.15_suppl.1018

Classe J-M, Loaec C, Gimbergues P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173:343–52.

doi: 10.1007/s10549-018-5004-7 pubmed: 30343457

Piltin M, Boughey J. Axillary management: how has neoadjuvant chemotherapy changed our surgical approach? Curr Breast Cancer Rep. 2022;14:1–7. https://doi.org/10.1007/s12609-022-00442-6 .

doi: 10.1007/s12609-022-00442-6

Boughey JC, Alvarado MD, Lancaster RB, et al. Surgical standards for management of the axilla in breast cancer clinical trials with pathological complete response endpoint. NPJ Breast Cancer. 2018;4:26.

doi: 10.1038/s41523-018-0074-6 pubmed: 30131975 pmcid: 6098077

Khan TM, Rossi AJ, Suman V, Haffty B, Hernandez JM, Boughey JC. Is axillary radiation not inferior to axillary dissection for sentinel lymph node-positive breast cancer after neoadjuvant chemotherapy? Ann Surg Oncol. 2022;29:1526–7.

doi: 10.1245/s10434-021-10830-4 pubmed: 34671883

Clinicaltrials.gov. I-SPY TRIAL: Neoadjuvant and personalized adaptive novel agents to treat breast cancer (I-SPY). https://clinicaltrials.gov/ct2/show/NCT01042379 . Accessed 20 March 2023.

Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86:97–100.

doi: 10.1038/clpt.2009.68 pubmed: 19440188

Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375:11–22.

doi: 10.1056/NEJMoa1513750 pubmed: 27406346 pmcid: 5259558

Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016;375:23–34.

doi: 10.1056/NEJMoa1513749 pubmed: 27406347 pmcid: 5259561

van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.

doi: 10.1056/NEJMoa021967 pubmed: 12490681

DeMichele A, Berry DA, Zujewski J, et al. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013;19:2817–23.

doi: 10.1158/1078-0432.CCR-12-2620 pubmed: 23470967 pmcid: 4096560

Yee D, DeMichele AM, et al. Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol. 2020;6:1355–62.

doi: 10.1001/jamaoncol.2020.2535 pubmed: 32701140

Piltin MA, Hoskin TL, Day CN, Davis J, Boughey JC. Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol. 2020;27:4795–801.

doi: 10.1245/s10434-020-08900-0 pubmed: 32779055

Nguyen TT, Hoskin TL, Day CN, et al. Decreasing use of axillary dissection in node-positive breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25:2596–602.

doi: 10.1245/s10434-018-6637-9 pubmed: 29978369

Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? results of a prospective study. Ann Surg Oncol. 2016;23:3467–74.

doi: 10.1245/s10434-016-5246-8 pubmed: 27160528 pmcid: 5070651

Srour MK, Tseng J, Luu M, Alban RF, Giuliano AE, Chung A. Patterns in the use of axillary operations for patients with node-positive breast cancer after neoadjuvant chemotherapy: a national cancer database (NCDB) analysis. Ann Surg Oncol. 2019;26:3305–11.

doi: 10.1245/s10434-019-07540-3 pubmed: 31342364

Naffouje SA, Barker V, Lee MC, Hoover SJ, Laronga C. Surgical management of axilla of triple-negative breast cancer in the Z1071 era: a propensity score-matched analysis of the national cancer database. Ann Surg Oncol. 2022;29:2985–97.

doi: 10.1245/s10434-021-11194-5 pubmed: 35006503

Naffouje SA, Sabesan A, Hoover SJ, Lee MC, Laronga C. Surgical management of the axilla of HER2+ breast cancer in the Z1071 era: a propensity-score-matched analysis of the NCDB. Ann Surg Oncol. 2021;28:8777–88.

doi: 10.1245/s10434-021-10411-5 pubmed: 34258723